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Impact of class III obesity on
outcomes and complications of
transvaginal ultrasound-guided
oocyte pickup
Tina Liang, M.D.,a Kelsey Ruetz, B.Sc.,b Olga Haakman, M.D.,a Angelos Vilos, M.D.,a George Vilos, M.D.,a
and Basim Abu-Rafea, M.D.a
a
Fertility Clinic, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Schulich
School of Medicine and Dentistry, Western University, London Health Sciences Centre; and b Schulich School of Medicine
and Dentistry, Western University, London, Ontario, Canada

Objective: To assess the impact of class III obesity on outcomes and complications of transvaginal ultrasound-guided oocyte pickup
(OPU).
Design: Retrospective cohort study.
Setting: Hospital-based fertility clinic.
Patient(s): All women undergoing OPU procedures during autologous in vitro fertilization (IVF) and oocyte banking cycles, grouped by
patient body mass index (BMI: <25, 25–29.9, 30–34.9, 35–39.9, R40 kg/m2).
Intervention(s): Transvaginal OPU under conscious sedation.
Main Outcome Measure(s): Sedation and procedure-related parameters and complications.
Result(s): A total of 2,141 OPU procedures in 1,579 patients were analyzed, including 121 OPU procedures in 94 patients with BMI
R40 kg/m2. There was a statistically signiﬁcant increase in total fentanyl and midazolam doses and procedure duration as BMI
increased. Compared with patients with BMI <25 kg/m2, those with BMI R40 kg/m2 were more likely to require additional sedation
during the procedure (adjusted odds ratio [aOR] 1.99; 95% conﬁdence interval [CI], 1.14–3.49). The rate of difﬁcult access was
28.9% for procedures with BMI R40 kg/m2 compared with 5.2% with BMI <25 kg/m2 (aOR 7.57; 95% CI, 4.66–12.29). The OPU
was incomplete due to inaccessible follicles through a transvaginal approach in 18.2% of procedures with BMI R40 kg/m2 compared
with 1.3% with BMI <25 kg/m2 (aOR 16.94; 95% CI, 8.24–34.84). The rates of sedation and procedure-related complications were low,
and none occurred in patients with BMI R40 kg/m2.
Conclusion(s): There was no increased risk of complications for women with class III obesity undergoing OPU with conscious sedation.
However, the operator was more likely to encounter difﬁcult access and to incompletely aspirate follicles through a transvaginal
approach. (Fertil Steril RepÒ 2020;1:270–6. Ó2020 by American Society for Reproductive Medicine.)
Key Words: BMI, obesity, oocyte pickup, oocyte retrieval
Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/xfre-d-20-00114

T

he prevalence of obesity, deﬁned
as body mass index (BMI) R30
kg/m2, has nearly tripled worldwide from 1975 to 2016 (1). Women
are also disproportionately affected
compared with men overall (2). The
prevalence of obesity among women

of reproductive age in Canada and the
United States is 22.7% (3) and 36.8%
(4), respectively, and 10% are in the
class III obesity category (BMI R40
kg/m2) in the United States (4).
Female obesity has adverse effects
on reproductive health, including an
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increased risk of menstrual dysfunction, oligo-ovulation, and infertility
(5). An increasing number of obese
women are presenting for fertility
care, but provision of assisted reproductive technology (ART) for these
women can be challenging due to concerns regarding procedural safety,
feasibility, and poor outcomes. Due to
these concerns, women with class III
obesity are frequently denied access to
ART treatment (6).
Transvaginal ultrasound-guided
oocyte pickup (OPU) during ART normally carries a low risk of complications (7). However, the additional
VOL. 1 NO. 3 / DECEMBER 2020
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concerns regarding the procedure for obese women include
anesthetic-related risks and technical difﬁculties such as
inability to access the ovaries (8, 9). Because of the paucity
of data on OPU-related outcomes in obese women compared
with normal-weight women, it is difﬁcult to determine when
ART may be offered safely and to appropriately counsel obese
women regarding their risks and expected outcomes. Our
study assessed the impact of class III obesity (BMI R40 kg/
m2) on outcomes and complications of transvaginal
ultrasound-guided OPU.

MATERIALS AND METHODS
We conducted a retrospective cohort study of all OPU procedures during autologous in vitro fertilization (IVF) and oocyte
banking cycles at the Fertility Clinic at London Health Sciences Centre, a university-afﬁliated, hospital-based fertility
clinic in London, Ontario, Canada, from January 1, 2013, to
November 30, 2019. Ethics approval was obtained from the
Western University Health Sciences Research Ethics Board
(115719). Cases of OPU with missing patient BMI information
or missing procedure records were excluded. Patient BMI was
calculated using weight measured at the start of each treatment cycle and height measured at initial patient consultation. We grouped OPUs by patient BMI based on the World
Health Organization classiﬁcation: normal and underweight
(BMI <25 kg/m2); overweight (BMI 25–29.9 kg/m2); class I
obesity (BMI 30–34.9 kg/m2); class II obesity (BMI 35–39.9
kg/m2); and class III obesity (BMI R40 kg/m2). Demographic
data for cycles were collected from the clinic’s electronic ART
database. The OPU outcomes and complications were
collected from the patients’ paper-based treatment charts
which contained procedure records as well as records of any
additional points of patient contact due to complications of
treatment.
Before undergoing fertility treatment, obese women with
comorbidities and all women with class III obesity were
referred to a multidisciplinary specialized obesity and pregnancy clinic led by a maternal-fetal medicine specialist. Patients underwent assessment and screening for
comorbidities including hypertension and diabetes, as well
as preconception counseling, nutritional assessment, and
follow up evaluation. All treatment cycles involved controlled
ovarian stimulation with gonadotropin-releasing hormone
(GnRH) antagonist, long GnRH agonist, or ﬂare GnRH agonist
protocols. Ultrasound monitoring was begun on day 4 or 5 of
stimulation until the lead follicle(s) reached 17–18 mm in
diameter. Final oocyte maturation was triggered with recombinant human chorionic gonadotropin (hCG) or GnRH
agonist, and OPU was performed 36 to 37 hours later.
The OPU procedures were routinely performed under
conscious sedation, deﬁned as a ‘‘drug-induced depression
of consciousness during which patients respond purposefully
to verbal commands, either alone or accompanied by light
tactile stimulation and no interventions are required to maintain a patent airway when spontaneous ventilation is
adequate’’ (10). This was administered using intravenous fentanyl and midazolam under the direction of the physician performing the OPU procedure. Additional fentanyl and/or
VOL. 1 NO. 3 / DECEMBER 2020

midazolam could be administered during the procedure as
needed, based on patient response. Occasionally on patient
request the OPU could be performed without sedation, deﬁned
as an awake state with normal response to verbal stimulation
without any intravenous or parenteral medications. Additionally, under rare circumstances of patient preference, OPU
could be performed under total intravenous anesthesia,
deﬁned as general anesthesia in an unconscious state using
intravenous propofol administered by an anesthesiologist.
Before 2015, paracervical blocks were also routinely performed in addition to sedation as per clinic protocol. This
was revised in 2015, and subsequent patients only received
sedation. Patients were monitored by continuous pulse oximetry and electrocardiogram along with intermittent noninvasive blood pressure recordings. As per clinic protocol,
antibiotic prophylaxis was routinely administered for all patients before the procedure with intravenous ceftriaxone or
clindamycin. If endometriomas or hemorrhagic cysts were
punctured during OPU, patients were given an additional
course of oral antibiotic prophylaxis after the procedure.
The speciﬁc regimen was determined by the physician performing the OPU.
All OPUs were performed using a transvaginal approach
under ultrasound guidance using a 17-gauge single-lumen
oocyte-aspiration needle mounted on a transvaginal probe
with needle guide. The OPU procedure was performed by a
reproductive endocrinology and infertility consultant on a
rotating schedule or by a clinical fellow under the direct supervision of a consultant. None of the physicians during the
study period performed OPUs using a transabdominal
approach.
Ovarian follicles were aspirated in the minimal possible
number of ovarian cortex punctures. Difﬁcult access was
noted during instances where external abdominal pressure
or suprapubic pressure were applied by an assistant to stabilize and access the ovary. If the ovary or a portion of the ovary
remained inaccessible through a transvaginal approach
despite multiple attempts, the procedure was discontinued,
and incomplete retrieval of follicles was noted. A speculum
examination was performed after the procedure. and any
vaginal bleeding was treated with direct pressure. Vaginal
bleeding that required repeated or prolonged pressure (R15
minutes total) or requiring additional intervention was recorded. The duration of procedure was recorded from the
time of fentanyl administration to the completion of the speculum examination.
After the procedure, patients were transferred to and
monitored in a recovery room for approximately 2 hours. Patients were required to tolerate oral intake, ambulate, and void
before discharge. Major sedation-related complications were
deﬁned as adverse events occurring as a result of intravenous
sedation that required transfer of the patient or admission to a
hospital. Transient episodes of desaturation <80% and heart
rate or blood pressure changes were recorded as minor
sedation-related complications. Patients were advised to contact the clinic or physician on call or present to our hospital
for any worsening abdominal pain, vaginal bleeding, or fevers after discharge from the clinic. Procedure-related
complication was deﬁned as an adverse event occurring as
271
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TABLE 1
Demographic characteristics of oocyte pickup according to body mass index.
BMI category (kg/m2)
Characteristic
Patient age at OPU (y)
Treatment indicationa
Endometriosis
Tubal factor
Male factor
PCOS
DOR
Unexplained
Fertility preservation
Other
Type of anesthesia
Conscious sedation
Total intravenous anesthesia
None

<25
(n [ 1,010)

25–29.9
(n [ 579)

30–34.9
(n [ 274)

35–39.9
(n [ 157)

‡40
(n [ 121)

P
value

33.7  4.3

34.2  4.2

34.2  4.1

34.1  4.0

34.1  3.6

.082

155 (15.3)
226 (22.4)
420 (41.6)
96 (9.5)
197 (19.5)
92 (9.1)
35 (3.5)
142 (14.1)

87 (15.0)
154 (26.6)
248 (42.8)
63 (10.9)
117 (20.2)
36 (6.2)
6 (1.0)
68 (11.7)

43 (15.7)
64 (23.4)
101 (36.9)
48 (17.5)
30 (10.9)
31 (11.3)
3 (1.1)
46 (16.8)

21 (13.4)
39 (24.8)
56 (35.7)
48 (30.6)
19 (12.1)
8 (5.1)
6 (3.8)
19 (12.1)

16 (13.2)
34 (28.1)
61 (50.4)
28 (23.1)
16 (13.2)
6 (5.0)
1 (0.8)
21 (17.4)

.936
.309
.061
< .001
.001
.022
.007
.212

1,005 (99.5)
0
5 (0.5)

577 (99.7)
1 (0.2)
1 (0.2)

274 (100)
0
0

157 (100)
0
0

121 (100)
0
0

—
—
—

Note: Data presented as mean  standard deviation for continuous variables or n (%) for dichotomous variables. BMI ¼ body mass index; DOR ¼ diminished ovarian reserve; OPU ¼ oocyte pickup;
PCOS ¼ polycystic ovary syndrome.
a
Treatment indications are not mutually exclusive.
Liang. Class III obesity and OPU outcomes. Fertil Steril Rep 2020.

a result of the retrieval aspect of OPU which required intervention outside of routine postprocedure care.
Data were analyzed using IBM SPSS Statistics, version 26
(IBM Corp.). Continuous variables were reported as mean and
standard deviation (SD), and categorical variables were expressed as percentages. Missing data were excluded from the
analysis for the speciﬁc variable. The chi square test was used
to test the association between two categorical variables.
One-way analysis of variance (ANOVA) with Tukey’s honestly signiﬁcant difference post hoc test was used to compare
differences in the mean between the BMI categories. Multiple
linear regression models were used to determine the relationship between a continuous outcome variable and several predictor variables, and binary logistic regressions assessed the
correlation between a dichotomous outcome and relevant independent variables. Regression models adjusted for potential
confounders included total number of follicles, diagnosis of
endometriosis, use of paracervical block, and ﬁrst cycle for
patient in study period. Multicollinearity was assessed using
the variance inﬂation factor, tolerance statistic, and condition
index. There were no high intercorrelations between any of
the independent variables. P< .05 was considered statistically
signiﬁcant.

RESULTS
During the study period, 2,157 OPU procedures were performed during autologous IVF and oocyte banking cycles. After excluding two OPU procedures with missing patient BMI
information and 14 OPU procedures with missing records, a
total of 2141 OPU procedures in 1,579 patients were included
for analysis. There were 1,010 OPUs in 736 patients with BMI
<25 kg/m2, 579 OPUs in 416 patients with BMI 25–29.9 kg/
m2, 274 OPUs in 210 patients with BMI 30–34.9 kg/m2, 157
OPU procedures in 123 patients with BMI 35–39.9 kg/m2,
272

and 121 OPU procedures in 94 patients with BMI R40 kg/
m2. Of the OPUs in the class III obesity category (BMI R40
kg/m2), there were 20 OPU procedures in 16 patients with
BMI R50 kg/m2, of which the highest BMI was 64. Table 1
shows the demographic characteristics of the patients undergoing OPU procedures according to BMI categories.
Of all included OPU procedures, 2,134 (99.7%) were performed under conscious sedation. Six procedures in ﬁve patients were performed without sedation, and one procedure
was performed under total intravenous anesthesia due to patient preference. The mean patient age at OPU was 34 years
across all BMI categories. There was no statistically signiﬁcant difference among the BMI categories in the proportion
of OPU procedures with a treatment indication of endometriosis; there were more OPU procedures in the higher BMI categories with a treatment indication of polycystic ovary
syndrome (PCOS).
Sedation-related outcomes of OPU are shown in Table 2.
As BMI increased, there was a statistically signiﬁcant increase
in the total dose of fentanyl and midazolam required. The OPU
procedures for patients with BMI R40 kg/m2 required mean
total fentanyl and midazolam doses of 111.2 mg and 2.6
mg, respectively, compared with 101.3 mg and 2.1 mg in
OPU procedures for patients with BMI <25 kg/m2. Obese patients were also more likely to require additional fentanyl
and/or midazolam during the procedure (17.8% of OPU procedures for BMI R40 kg/m2 compared with 10.3% of OPU
procedures for BMI <25 kg/m2).
Procedure-related outcomes of OPU are shown in Table 3.
As BMI increased above 30 kg/m2 there was a statistically signiﬁcant increase in the duration of procedure as well as the
rate of difﬁcult access to ovaries and rate of incomplete
retrieval of follicles. The mean procedure duration was 15.7
minutes for BMI R40 kg/m2 compared with 13.3 minutes
for BMI <25 kg/m2 (P< .001). The rate of difﬁcult access
VOL. 1 NO. 3 / DECEMBER 2020
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TABLE 2
Sedation-related outcomes of oocyte pickup according to body mass index.
BMI category (kg/m2)
Outcome

<25
(n [ 1,005)

25–29.9
(n [ 577)

P
value

30–34.9
(n [ 274)

P
value

35–39.9
(n [ 157)

P
value

‡40
(n [ 121)

P
value

Total fentanyl dose (mg)
Regression coefﬁcient B (95% CI)
Total midazolam dose (mg)
Regression coefﬁcient B (95% CI)
Additional sedation requireda
aOR (95% CI)

101.3  25.4
Reference
2.1  1.2
Reference
87 (10.3)
Reference

104.9  21.4
3.4 (1.1, 5.6)
2.2  1.2
0.1 (0.04, 0.2)
52 (10.6)
1.09 (0.75, 1.57)

.004

108.0  22.4
6.2 (3.2, 9.1)
2.4  1.2
0.4 (0.3, 0.5)
44 (18.6)
1.95 (1.30, 2.93)

< .001

114.8  25.8
12.3 (8.6, 16.0)
2.5  1.0
0.3 (0.2, 0.4)
25 (17.9)
1.92 (1.17, 3.16)

< .001

111.2  23.7
9.6 (5.5, 13.8)
2.6  1.2
0.4 (0.2, 0.5)
19 (17.8)
1.99 (1.14, 3.49)

< .001

.003
.665

< .001
.001

< .001
.010

< .001
.016

Note: Data presented as mean  standard deviation for continuous variables or n (%) for dichotomous variables. Regression models adjusted for number of follicles, diagnosis of endometriosis, use of paracervical block and ﬁrst cycle for patient in study period. aOR ¼
adjusted odds ratio; BMI ¼ body mass index; CI ¼ conﬁdence interval.
a
Data unavailable for 318 oocyte pickups.
Liang. Class III obesity and OPU outcomes. Fertil Steril Rep 2020.

TABLE 3
Procedure-related outcomes of oocyte pickup according to body mass index.
BMI category (kg/m2)
Outcome
Procedure duration (min)a
Regression coefﬁcient B
(95% CI)
Difﬁcult access
aOR (95% CI)
Incomplete retrieval
aOR (95% CI)

<25
(n [ 1,010)

25–29.9
(n [ 579)

P
value

13.3 (5.3)
Reference

13.1 (5.6)
0.1 (0.6, 0.5)

.813

14.6 (5.3)
1.1 (0.4, 1.9)

53 (5.2)
Reference
13 (1.3)
Reference

40 (6.9)
1.35 (0.88, 2.06)
8 (1.4)
1.09 (0.45, 2.64)

.167

39 (14.2)
3.07 (1.98, 4.76)
18 (6.6)
5.34 (2.58, 11.06)

.854

30–34.9
(n [ 274)

P
value

35–39.9
(n [ 157)

P
value

‡40
(n [ 121)

P
value

.002

15.5 (6.0)
2.1 (1.2, 3.0)

< .001

15.7 (6.3)
2.7 (1.7, 3.7)

< .001

< .001

24 (15.3)
3.41 (2.03, 5.72)
9 (5.7)
4.63 (1.94, 11.04)

< .001

< .001

.001

35 (28.9)
7.57 (4.66, 12.29)
22 (18.2)
16.94 (8.24, 34.84)

< .001
< .001

Liang. Class III obesity and OPU outcomes. Fertil Steril Rep 2020.
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Note: Data presented as mean  standard deviation for continuous variables or n (%) for dichotomous variables. Regression models adjusted for number of follicles, diagnosis of endometriosis, use of paracervical block and ﬁrst cycle for patient in study period. aOR ¼
adjusted odds ratio; BMI ¼ body mass index; CI ¼ conﬁdence interval.
a
Data unavailable for 205 oocyte pickups.
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TABLE 4
Complications of oocyte pickup according to body mass index.
BMI category (kg/m2)
Complication

<25
(n [ 1,010)

25–29.9
(n [ 579)

30–34.9
(n [ 274)

35–39.9
(n [ 157)

‡40
(n [ 121)

4 (0.4)

0

0

0

0

2 (0.2)
0

0
0

0
1 (0.4)

0
0

0
0

2 (0.2)
3 (0.3)
1 (0.1)

0
0
0

0
0
0

4 (2.5)
0
0

0
0
0

Minor sedation-related
complication
Transient desaturation
<80%
Transient bradycardia
Transient hypotension
Procedure-related
complication
Vaginal bleeding
Hemoperitoneum
Bladder injury
Note: Data presented as n (%). BMI ¼ body mass index.

Liang. Class III obesity and OPU outcomes. Fertil Steril Rep 2020.

was 28.9% for BMI R40 kg/m2 compared to 5.2% for BMI
<25 kg/m2 with adjusted odds ratio (aOR) of 7.57 (95% CI,
4.66–12.29), while the rate of incomplete retrieval was
18.2% compared with 1.3% with aOR of 16.94 (95% CI,
8.24–34.84). Of the OPUs with incomplete retrievals, two procedures were discontinued in patients with BMIs of 40.3 and
42.5 before aspiration of any follicles as both ovaries were
deemed inaccessible transvaginally.
All OPU complications were diagnosed during or shortly
after the procedure before patient discharge. No OPU complications occurred in patients with BMI R40 kg/m2 during the
study period (Table 4). There were no major sedation-related
complications, and there were seven minor sedation-related
complications (0.3% overall) consisting of transient episodes
of desaturation <80%, bradycardia, and hypotension. Of
these, six complications occurred in patients with BMI <25
kg/m2 (0.6%), and one in patients with BMI 30–34.9 kg/m2
(0.4%). These were all resolved with patient arousal and a
short period of supplemental oxygen in the procedure room.
None required further intervention in the recovery room.
There were a total of 10 procedure-related complications
(0.5% overall) with six in patients with BMI <25 kg/m2 (0.6%)
and four in patients with BMI 35–39.9 kg/m2 (2.5%). All six
cases of vaginal bleeding were resolved with direct pressure
up to 30 minutes (n ¼ 3) or vaginal sutures (n ¼ 3). Two of
three cases of hemoperitoneum were admitted to hospital
for observation and were discharged within 48 hours without
further intervention. None required a blood transfusion. One
patient sustained a minor bladder injury identiﬁed by postprocedure hematuria, which resolved spontaneously and did
not require intervention.

DISCUSSION
Data from our center showed that women with class III obesity
required a small but statistically signiﬁcant increase in total
dose of sedation medications and longer duration of procedure compared with normal-weight and underweight women
during OPU. Although the operators were more likely to
274

encounter difﬁcult access and to incompletely retrieve
ovarian follicles through a transvaginal approach for women
with class III obesity, there was no increased risk of sedation
or procedure-related complications for these women in our
data set.
The literature on outcomes of conscious sedation among
obese women is limited. Our observation of an increase in fentanyl and midazolam dose associated with increasing BMI is
in keeping with two studies of other procedures using
conscious sedation including bronchoscopy and ﬁrsttrimester surgical abortion (11, 12). Similarly, an increase in
propofol dose has been observed with increasing BMI in
endoscopy under deep sedation (13), as well as OPUs for
IVF under total intravenous anesthesia (9). This may be a
result of increased volume of distribution of drugs due to
higher percentage of body fat.
Similar to the observation of longer time spent in the
operating room for obese patients undergoing OPU procedures under total intravenous anesthesia (9), we also observed
an increase in the duration of the procedure, although our
ﬁnding does not take into account the time needed to position
and transfer patients before and after the procedure. Nevertheless, our increase in procedure time is likely a reﬂection
of additional time necessary to achieve optimal view on ultrasound and obtain safe access to the ovary in obese women.
We found a statistically signiﬁcant increase in incidence
of difﬁcult access in women with obesity, necessitating
abdominal or suprapubic pressure by an assistant. This association also accounts for the increased incidence of incomplete retrieval of follicles in women with obesity, including
two women with class III obesity where no follicles were
retrievable. At our center, every effort was made to retrieve
the maximal number of follicles transvaginally, after which
the procedure was discontinued despite the presence of remaining follicles because we do not perform transabdominal
retrievals. The transabdominal approach for OPU has been
used for patients with ovaries inaccessible by the transvaginal
approach (14–16), and has been used more frequently in
women with class III obesity (9).
VOL. 1 NO. 3 / DECEMBER 2020
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Our data showed no major sedation-related complications and seven cases of minor sedation related complications
consisting of transient episodes of desaturation, bradycardia,
and hypotension, with all but one case occurring in the
normal and underweight category. This is reassuring and supports the use of conscious sedation over deeper levels of sedation or general anesthesia in obese women. We also found
that women with obesity were more likely to require additional sedation medications during the procedure, which suggests a comparative lighter level of sedation with the initial
dosage of fentanyl and midazolam. This likely contributes
to the low sedation related complication rate in these women.
Given sedation is a continuum, and the variation in individual
patient response which cannot always be predicted, the safest
approach is to administer sedation in small incremental doses
and titrate to a desired response (10, 17). Additionally, a contingency plan must be in place in cases where the level of
sedation becomes deeper than initially intended (10). Hence,
we agree with Romanski et al. (9) that the availability of
appropriate resources, such as in our hospital-based clinic
setting, is important for treating women with obesity.
The only procedure-related complications we observed in
obese women were four cases (2.5%) of vaginal bleeding in
women with class II obesity, which were all managed with
pressure or suture. This rate is in keeping with previously reported rates of vaginal bleeding after OPU in all women,
which varies widely from 0.01% to 3.0%, likely due to variations in the deﬁnition used for the outcome (18–21).
Therefore, this is reassuring for the question of procedural
safety in women with higher class obesity.
This is one of few studies examining the outcomes and
safety of OPU in women with obesity undergoing ART. To
our knowledge, it is the only study including women with
class III obesity undergoing OPU procedures with conscious
sedation, a method of analgesia widely used in IVF centers.
It provides valuable information for counseling patients
with obesity before ART.
Although we controlled for various confounders in the
assessment of OPU outcomes in relation to BMI, our data did
not contain experience level of the operator performing the
OPU (fellow versus staff or consultant). This is a variable that
has been previously shown to affect OPU outcomes (19).
Because our center does not routinely perform OPU procedures
through a transabdominal approach, patients who were identiﬁed as having inaccessible ovaries transvaginally before their
treatment cycle were referred to other centers for transabdominal OPU procedures and were not included in our study.
Although the recording of difﬁcult access was a routine
aspect of the OPU record, we cannot be certain that every
instance was recorded due to the retrospective nature of the
study. The recording of difﬁcult access and incomplete
retrieval also did not routinely indicate a speciﬁc cause that
may be unrelated to BMI such as uterine ﬁbroids. Additionally, although patients were advised to contact our clinic or
present to our hospital for concerns after discharge from the
clinic, it is possible patients may have sought care in the community for complications without our knowledge. Therefore,
there is the possibility of missing complications from our
database.
VOL. 1 NO. 3 / DECEMBER 2020

CONCLUSION
We found no increased risk of sedation or procedure-related
complications in OPU procedures performed under conscious
sedation in women with class III obesity. However, the operator performing the OPU was more likely to encounter difﬁcult access to the ovary and to incompletely aspirate
follicles through a transvaginal approach in this patient
population.
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